Jerome Kim | Director General

Jerome Kim, Director General, IVI

Jerome H. Kim, M.D., is an international expert on the development and evaluation of vaccines and is the Director General of the International Vaccine Institute (IVI).  He has unparalleled experience and success in translating innovation to impact – working with key national and international stakeholders, creating a common understanding of the value proposition, developing and executing creative strategies for sustainable growth.  At IVI he led and grew a team whose mission is to discover, develop and deliver safe, effective, and affordable vaccines for Global Health from a small Korea-based international organization to one with a global footprint and diverse and expanding funding. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease.  IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience and PT BioFarma; the SK TCV is now approved by the Korean Ministry of Food and Drug Safety and has received WHO PQ.  BioFarma’s vaccine has been approved by the Indonesian BPOM. Prior to joining IVI, he was the Program Manager for the Army’s Advanced Development Program for HIV vaccines and led the only HIV vaccine trial to show protection against infection (RV144), the identification of correlates from the trial, and analysis of viral sieve effects.  He was also the Principal Deputy of the US Military HIV Research Program doing earlier stage R&D on HIV vaccines and the Chief, Laboratory of Molecular Virology and Pathogenesis, Walter Reed Army Institute of Research.  Dr. Kim is a Distinguished Visiting Professor, Seoul National University; Adjunct Professor at the Uniformed Services University (USA) and the Graduate School of Public Health, Yonsei University; and is an Honorary Professor, University of Rwanda and the University of Hong Kong.   Dr. Kim graduated from the University of Hawaii with High Honors in History and Highest Honors in Biology, winning the Arthur Lyman Dean Prize in the Humanities and the Library Prize in Pacific Islands Area Research.  Dr. Kim received his M.D. from the Yale University School of Medicine and completed Internal Medicine Residency and Infectious Diseases Fellowship at Duke University Medical Center.  He has authored over 350 publications and has received numerous awards, including the Medal of Honor for Civic Merit, Republic of Korea.


Pre-Congress Workshops - Monday 28th October @ 10:00

Biothreats & Disease X Workshop [AM2]

Pre-Congress Workshops - Monday 28th October @ 14:00

Vaccine Equity Workshop [PM2]

Day 2 - Wednesday 30th October @ 08:40

Turning Target to Treatment: What Is The Pathway From A Priority Pathogen List To Vaccines?

-      What are our most challenging and urgent vaccine targets?

-      Which of our most stubborn targets with unmet R&D needs pose a great global threat?

-      How do we prioritise development to balance the threat of viral diseases and antibiotic overconsumption with the urgency of addressing highly resistant bacterial infections?

-      How can we best align these efforts with our global priorities and the pandemic accord?

-      Priorities & considerations for developing vaccines: pandemic & endemic

Introducing the WHO Pandemic and Endemic pathogen lists, followed by panel:

Dr Ana Maria Henao-Restrepo, Leader, R&D Blue Print, WHO - TBC

Dr Martin Friede, Co-ordinator, Initiative for Vaccine Research, WHO

Dr Jerome Kim, Director General, IVI

Prof Lucy Chappell, Chief Scientific Adviser, UK Department of Health and Social Care - TBC

Senior Representative, Africa CDC - TBC

last published: 10/Jul/24 14:15 GMT

back to speakers